41
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Post-thymectomy, Seronegative Myasthenia Gravis

, &
Pages 7-12 | Accepted 04 Oct 2007, Published online: 08 Jul 2009

REFERENCES

  • Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001; 357: 2122–2128
  • Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalized myasthenia gravis: Clinical features, antibodies, and their targets. Lancet Neurol. 2003; 2: 99–106
  • Masaoka A, Yamakawa Y, Niwa H, Fukai I, Kondo S, Kobayashi M, Fujii Y, Monden Y. Extended thymectomy for myasthenia gravis patients: A 20 year review. Ann Thorac Surg. 1996; 62: 853–859
  • Budde J M, Morris C D, Gal A A, Mansour K A, Miller J I, Jr. Predictors of outcome in thymectomy for myasthenia gravis. Ann Thorac Surg 2001; 72: 197–2002
  • Haniuda M, Kondo R, Numanami H, Makiuchi A, Machida E, Amano J. Recurrence of thymoma: Clinicopathological features, re-operation and outcome. J Surg Oncol 2001; 78: 183–188
  • Ito M, Fujimura S, Monzen Y, et al. A retrospective group study on post-thymectomy myasthenia gravis. J Jpn Assoc Thorac Surg 1992; 19: 189–193
  • Wakata N, Fukuya H, Niizuma M, Ishida T, Kinoshida M. Myasthenia gravis developing after discovery of thymoma. Clin Neurol Neurosurg 1992; 94: 303–306
  • Kupersmith M J, Fazzone H E. Comparing ocular muscle limitation tests for clinical trial use. Arch Ophthalmol Mar, 2004; 122(3)347–348
  • Richman D P, Agius M A. Treatment of autoimmune myasthenia gravis. Neurology 2003; 61: 1652–1661
  • Guillermo G R, Tellez-Zenteno Z F, Weder-Cisneros N, Mimenza A, Estanol B, Remes-Troche J M, Cantu-Brito C. Response of thymectomy: Clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients. Acta Neurol Scand 2004; 109: 217–221
  • Truffault F, Cohen-Kaminsky S, Khalil I, Levasseur P, Berih-Aknins S. Altered intrathymic T-cell repertoire in human myasthenia gravis. Ann Neurol 1997; 41: 731–741
  • Buckley C, Douek D, Newsom-Davis J, Vincent A, Wilcox N. Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis. Ann Neurol 2001; 50: 64–72
  • Levinson A I, Song D, Gaulton G, Zheng Y. The intrathymic pathogenesis of myasthenia gravis. Clin Dev Immunol 2004; 11: 215–220
  • Solliven B C, Lange D J, Penn A S, Younger D, Jaretzki A, Lovelace R E, Rowland L P. Seronegative myasthenia gravis. Neurology 1988; 38: 514–517
  • Asakawa H, Kashihara T, Fukuda H, Yamamoto M. A patient with thymoma and four different organ-specific autoimmune diseases. Neth J Med 2002; 60: 292–295
  • Aarli J A, Gilhus N E, Matre R. Myasthenia gravis with thymoma is not associated with an increased incidence of non-muscle autoimmune disorders. Autoimmunity 1992; 11: 159–162
  • Schluep M, Wilcox N, Vincent A, Dhoot G K, Newsom-Davis J. Acetylcholine receptors in human thymic myoid cells in situ: an immunohistochemical study. Ann Neurol. 1987; 22: 212–222
  • Caress J B, Hunt C H, Batish S D. Anti-MuSK myasthenia gravis presenting with purely ocular findings. Arch Neurol 2005; 62(6)1002–1003

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.